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Abstract
Mice with targeted deletion of STAT3 in CD4
+ T-cells do not develop experimental autoimmune uveitis (EAU) or
experimental autoimmune encephalomyelitis (EAE), in part, because they cannot generate pathogenic Th17 cells. In this
study, we have used ORLL-NIH001, a small synthetic compound that inhibits transcriptional activity of STAT3, to ameliorate
EAU, an animal model of human posterior uveitis. We show that by attenuating inflammatory properties of uveitogenic
lymphocytes, ORLL-NIH001 inhibited the recruitment of inflammatory cells into the retina during EAU and prevented the
massive destruction of the neuroretina caused by pro-inflammatory cytokines produced by the autoreactive lymphocytes.
Decrease in disease severity observed in ORLL-NIH001-treated mice, correlated with the down-regulation of a4b1 and a4b7
integrin activation and marked reduction of CCR6 and CXCR3 expression, providing a mechanism by which ORLL-NIH001
mitigated EAU. Furthermore, we show that ORLL-NIH001 inhibited the expansion of human Th17 cells, underscoring its
potential as a drug for the treatment of human uveitis. Two synthetic molecules that target the Th17 lineage transcription
factors, RORct and RORa, have recently been suggested as potential drugs for inhibiting Th17 development and treating
CNS inflammatory diseases. However, inhibiting STAT3 pathways completely blocks Th17 development, as well as, prevents
trafficking of inflammatory cells into CNS tissues, making STAT3 a more attractive therapeutic target. Thus, use of ORLL-
NIH001 to target the STAT3 transcription factor, thereby antagonizing Th17 expansion and expression of proteins that
mediate T cell chemotaxis, provides an attractive new therapeutic approach for treatment of posterior uveitis and other CNS
autoimmune diseases mediated by Th17 cells.
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Introduction
T-helper cells are immune cells that mediate adaptive immunity
in vertebrates and are comprised of 4 major subtypes, Th1, Th2,
Th17 and Treg [1,2,3]. In comparison to other T-helper subsets,
IL-17-producing T cells (Th17) are present in very low amounts in
human blood but become highly elevated during chronic
inflammation and are implicated in the pathology of several
autoimmune diseases and chronic inflammatory disorders [4].
Th17 are therefore the subjects of intense research because they
are potential drug targets for treating these disorders [5,6,7]. The
differentiation of naı ¨ve CD4
+ T cells towards the Th17
developmental pathway is promoted by IL-6 and TGF-b and
mediated through activation of STAT3 pathways and Th17
lineage-specific transcription factors, RORa and RORct [1,3,8].
Loss of STAT3 or RORct expression abrogates Th17 differen-
tiation and inhibits the production of cytokines secreted by Th17
cells [9]. In line with their role in Th17 differentiation, STAT3
and RORct are attractive targets for treating autoimmune diseases
such as uveitis, multiple sclerosis and inflammatory bowel disease.
Human uveitic diseases are estimated to be the cause of about
10% of severe visual loss in the United States and current
understanding of the pathophysiology of uveitis derives largely
from study of experimental autoimmune uveitis (EAU), a mouse
model that shares essential features with human uveitis [10,11].
Analysis of the recruitment of T cells from peripheral lymphoid
tissues into the retina during EAU, revealed tremendous increase of
Th17 cellsinthe blood,lymphnodesand retinaofmiceatonset and
peak ofthe disease [4,12]. However,theirlevelsdecline atlate stages
associated with recovery from acute uveitis [4,12]. Treatment with
anti-IL-17 antibodies ameliorated the disease, underscoring the
involvementofTh17cellsinEAUpathology[4,12]. Consistentwith
the role of Th17 in etiology of uveitis, mice with targeted deletion of
STAT3 in the CD4
+ T cell compartment (CD4-STAT3KO) are
resistant to development of EAU [12]. CD4-STAT3KO mice are
also resistant to experimental autoimmune encephalomyelitis
(EAE), an animal model of human multiple sclerosis, further
underscoring requirement of STAT3 pathway in CNS inflamma-
tory diseases [13]. In EAU, significant numbers of the Th17 cells
also express IFN-c (Th17-DP) [4,12]. These double expressors are
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aabsentinCD4-STAT3KOmice[12,14,15],indicating that theyare
also regulated by STAT3 and raising the intriguing possibility that
uveitis maybe mediated not only by Th17 but also by Th17-DP
cells. Requirement of STAT3 for generation of Th17 and Th17-DP
cells also suggest that the STAT3 pathway is a potential therapeutic
target that may be used to prevent or mitigate uveitis.
In this study, we induced EAU in B10.A mouse strain by
immunization with interphotoreceptor-retinoid-binding protein
(IRBP) [11]. We show here that a synthetic small molecule
(ORLL-NIH001) that inhibits STAT3 reduced the severity of
EAU by inhibiting Th17 expansion and inhibiting the expression
of proteins that mediate the recruitment of inflammatory cells into
the neuroretina. We further show that ORLL-NIH001 blocked
the transcriptional activity of STAT3 and antagonized the
expansion of human Th17 cells, providing suggestive evidence
that it can be used to treat uveitis and other chronic inflammatory
diseases caused by Th17 and Th17-DP cells.
Materials and Methods
Normal human subjects
Blood samples were obtained after IRB approval and consent
from 10 normal human subjects that voluntarily donated blood to
the National Institutes of Health (NIH) Blood Bank administered by
the NIH Department of Transfusion Medicine. Each blood donor
reads and signs consent form approved by the NIH ethics and
intramural institute review boards. NIH Department of Transfusion
Medicine adheres to the Declaration of Helsinki on research on
human subjects. PBMCs were isolated from heparin treated whole
blood by density gradient centrifugation and CD4
+ T cells were
isolated using the Rosette Sep kit (Stem Cell Tech, VA, Canada).
PBMC or CD4
+ cells were stimulated for 4 days with human anti-
CD3 Abs (1 mg/ml), anti-CD28 Abs (3 mg/ml) in medium
containing ORLL-NIH001 or vehicle. In some experiments
exogenous IL-6 (10 ng/ml) (R&D Systems Minneapolis, MN) was
added to medium.
Mice
C57BL/6 and B10.A mice (6–8 weeks old) were from Jackson
Laboratory (Bar Harbor, ME). Mice with conditional deletion of
STAT3 in CD4 T cell compartment (CD4-STAT3KO) have been
described [12]. Animal care and use was in compliance with
Association for Assessment and Accreditation of Laboratory
Animal Care, International (AAALAC) and the NIH Intramural
Animal Care & Use Program guidelines. This study was approved
by the National Eye Institute/NIH Animal Care and Use
Committee under the Animal Study Proposal (ASP) # NEI-597
approved on October 25, 2010).
Drug: ORLL-NIH001
ORLL-NIH001 is a synthetic small chemical compound
developed by Orchid Research Laboratories Limited, Chennai,
India. ORLL-NIH001 is a small molecule of 406-kDa with 98%
purity as determined by HPLC and has been shown in various pre-
clinical in vitro and in vivo models of oncology to be an inhibitor of
pSTAT3. In pilot studies several doses (1 mg, 5 mg, 10 mg, 30 mg,
50 mg/kg/mouse) were administered intravenously to IRBP-
immunized mice:10 mg/kg/mouse wasfoundto be mostefficacious
dose. Drug was solubilized in Vehicle [aqueous mixture of Hydroxyl
propyl b-cylodextrin (0.2 g/ml), succinic acid (0.1 g/ml)].
Induction of EAU and Histology
EAU was induced by active immunization with bovine
interphotoreceptor retinoid-binding protein (IRBP), using 150 mg
for C57BL/6 mice and 50 mg for B10.A mice and human IRBP
peptide, amino acid residues 1–20, (150 mg for C57BL/6 mice), in
a 0.2 ml emulsion (1:1 v/v with complete Freund’s adjuvant (CFA)
containing mycobacterium tuberculosis strain H37RA (2.5 mg/
ml). Mice also received Bordetella pertussis toxin (0.2 mg/mouse)
concurrent with immunization. Mice were divided into 2
treatment groups. Mice in Protocol 1, received the drug starting
1 day prior to immunization with IRBP/CFA (day 21) and every
other day thereafter until day 17 after immunization. Mice in
Protocol 2 began receiving the drug 5 days post-immunization and
every other day thereafter until day 17 post-immunization. Mice
were sacrificed on day 18 post immunization, a time point that
coincides with peak EAU in mice [12]. Eyes for histological EAU
evaluation were harvested 18 days post-immunization, fixed in
10% buffered formalin and serially sectioned in the vertical
pupillary-optic nerve plane. Sections were stained with hematox-
ylin and eosin (H&E) and EAU was scored in a masked fashion
from 0 to 4 according to the histopathologic grading method
developed previously for murine EAU by Chan et al [16]. Severity
of EAU was scored according to the following criteria: 0, no sign of
infiltrate; 0.5, focal non-granulomatous, monocytic infiltration in
the choroid, ciliary body and retina; 1, retinal perivascular
infiltration and monocytic infiltration in the vitreous; 2, granuloma
in uvea, presence of retinal vasculitis, photoreceptor folds, serous
detachment and loss of photoreceptor; 3 or 4, presence of Dalen-
Fuchs nodules (granuloma at the level of the retinal pigmented
epithelium) and subretinal neovascularization and depending on
the number and size of the lesions. For analysis of T cells that
infiltrated the retina during EAU, eyes were dissected and retinas
were minced and incubated shaking at 37uC for 60 min in RPMI-
1640 media containing 0.5 mg/ml of collagenase type D
(Worthington, New Jersey). Released cells were subjected to flow
cytometric analysis using appropriately labeled mAbs specific to
relevant mouse T cell surface marker.
Analysis of CD4
+ T-helper cells
Freshly isolated T cells or IRBP-stimulated T cells from blood,
spleen, lymph nodes (LN) or retina were analyzed for expression of
inflammatory proteins by FACS or the intracellular cytokine
expression assay as described [17]. In some experiments naı ¨ve T
cells were activated in plate-bound anti-CD3 Abs (10 mg/ml) and
soluble anti-CD28 Abs (3 mg/ml) without exogenous cytokines or
Abs (Th0) or under Th17 [anti-CD3/CD28 Abs, IL-6 (10 ng/ml),
TGF-b1 (2 ng/ml), anti-IFN-c Abs (10 mg/ml), anti-IL-4 Abs
(10 mg/ml)] polarization condition. For intracellular cytokine
detection, cells were re-stimulated for 5 h with PMA (20 ng/
ml)/ionomycin (1 mM). Golgi-stop was added in the last hour and
intracellular cytokine staining was performed using BD Bioscienc-
es Cytofix/Cytoperm kit (BD Pharmingen, San Diego, CA). FACS
analysis was performed on a Becton-Dickinson FACSCalibur
using labeled monoclonal and corresponding isotype control Abs
(PharMingen). Detection of intracellular pSTAT proteins was as
described by [18] with fixation of the cells in 1.6% formaldehyde
and permeabilized in 100% methanol. Fluorochrome-conjugated
pSTAT1, 23, and 25 antibodies were purchased from BD-
Bioscience.
Lymphocyte proliferation assay
T cells were cultured for 4 d in quintuplet cultures containing
anti-CD3/CD28 Abs and CFSE (carboxyfluorescein succinimidyl
ester). CFSE dilution assay was performed using a commercially
available CFSE Cell Proliferation Kit (Molecular Probes, Inc.,
Eugene, OR). After 36 h, some cultures were pulsed with
3H-
thymidine (0.5 mCi/10 ml/well) for 12 additional hours and
Small Molecule Inhibitor of STAT3 Inhibits Uveitis
PLoS ONE | www.plosone.org 2 January 2012 | Volume 7 | Issue 1 | e29742analyzed. The
3H-thymidine incorporation assay data are mean
CPM 6 S.E. of responses of five replicate cultures. CFSE dilution
assay and
3H-Thymidine incorporation were performed on
different samples.
Western blotting analysis
Preparation of whole cell lysates and immunodetection were
performed as described [19]. Samples (20 mg/lane) were fraction-
ated on 4–20% gradient SDS-PAGE, and antibodies used were:
pSTAT1, pSTAT3, pSTAT5 (Cell Signaling Technology) and b-
Actin (Santa Cruz Biotechnology, Santa Cruz, CA). Preimmune
serum was used in parallel as controls and signals were detected
with HRP-conjugated secondary F(ab’)2 Ab (Zymed Laboratories)
using the ECL-PLUS system (Amersham, Arlington Heights, IL).
Some blots were analyzed with the NIH Image Quant program.
Each band was normalized to corresponding b-actin band and
expressed in arbitrary relative protein expression units.
Statistical analysis
Statistical analyses were performed by independent two-tailed
Student’s t test. Probability values of #0.05 were considered
statistically significant. The data are presented as mean+SD.
Results
STAT3 signal is required for recruitment of T cells into
retina and development of EAU
EAU was induced in WT or CD4-STAT3KO by immunization
with IRBP in CFA, and consistent with previous studies, all WT
mice developed severe EAU characterized by targeted destruction
of photoreceptor cells [11] while none of the CD4-STAT3KO
developed EAU (Fig. 1A). Intracellular cytokine staining analysis
of the levels of STAT3 activation in the lymph nodes (LN) and
spleen revealed substantial increase in pSTAT3 in mice with EAU
compared to control mice (Fig. 1B). The positive correlation
between high levels of pSTAT3 and increase of Th17 cells in the
LN and spleen underscore the involvement of STAT3 signaling
pathways for differentiation/expansion of Th17 cells that mediate
EAU. We also observed substantial increase of CD4
+ T cells in the
retina of WT mice and the CD4
+ T cell repertoire was
characterized by the presence of Th17, Th1 and Th17-DP cells
in the retina (Fig. 1C). In contrast, CD4
+ T cells were barely
detectable in the retina of IRBP-immunized CD4-STAT3KO
mice. Taken together, these results suggest that STAT3 signaling is
required for recruitment of T cells into retina and development of
EAU and that drugs that block STAT3 signal transduction
pathway may be useful in mitigating uveitis.
A STAT3 inhibitor chemical (ORLL-NIH001) conferred
protection from severe EAU
The studies showing that mice with targeted deletion of STAT3
in T cells could not develop EAU [12] or EAE [12,13] provided
the requisite proof-of-principle experiments that spurred interest in
the use of STAT3 antagonist as potential drugs for inhibiting
Th17-mediated inflammatory diseases. In this study, we examined
whether ORLL-NIH001, an inhibitor of STAT3, would be
efficacious in mitigating uveitis. We induced EAU in B10.A mice
by active immunization with IRBP and the mice were treated with
varying doses of ORLL-NIH001, ranging from 1 mg/kg/mouse
to 50 mg/kg/mouse per day. These pilot studies established that
administration of 10 mg/kg/mouse by intravenous (i.v.) was most
efficacious. The experimental design is depicted in Figure 2A. Aim
of Protocol 1 study was to determine whether the drug could
prevent development of EAU while Protocol 2 assessed whether
the drug could reduce severity of ongoing disease. In Protocol 1,
36 mice (12 mice/experiment) received the drug at the times
indicated (Fig. 2A), starting 1 day before immunization (day 21).
In Protocol 2, each of 36 mice (12 mice/group) received the drug,
starting on day 5 post-immunization and then every other day
until day 17 post-immunization. For both protocols, age-match
control mice were also immunized but they did not receive the
drug. We show here that EAU was very severe in the B10.A mouse
Figure 1. STAT3-deficient T cells could not traffic into the retina nor induce EAU. (A) WT mice or mice with targeted deletion of STAT3 in T
cells (CD4-STAT3KO) were immunized with IRBP in CFA and their eyes were enucleated 21 days post-immunization and histological sections through
the retina were stained with H&E. Black arrows indicate presence of inflammatory cells in the vitreous (V) and blue arrows depict pathologic foci
characterized by the presence of retinal folds and hemorrhage. Red arrow, choroiditis; White arrow, granuloma; green arrow, retinal vasculitis; OpN,
optic nerve; V, vitreous; GCL, ganglion cell layer; INL, inner nuclear layer; ONL, outer nuclear layer. (B) Freshly isolated cells from the draining lymph
nodes or spleen of WT unimmunized WT control or EAU mice were analyzed by the intracellular cytokine assay. Plots were gated on CD4
+ T cells and
numbers in quadrants indicate percentage of CD4
+ T cells expressing IL-17 and/or activated STAT3 (pSTAT3). (C) WT or CD4-STAT3KO mice were
immunized with IRBP in CFA and T cells present in retina on day-21 post-immunization were detected and quantified by flow cytometry. Numbers in
quadrants indicate percentage of CD3
+ or CD4
+ T cells or CD4
+ T cells expressing IL-17 and/or IFN-c. Data presented are representative of at least 3
independent experiments.
doi:10.1371/journal.pone.0029742.g001
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the retina, vitreous and optic nerve (Fig. 2B; left panel). On the
other hand, we observed dramatic reduction in the numbers of
cells infiltrating the retina of mice treated with the drug (Fig. 2B;
right panel) and the decrease in inflammation in drug-treated mice
coincided with lower EAU scores (Fig. 2C). Similar to mice treated
under Protocol 1, mice that began receiving the drug 5 days after
T cell priming (Protocol 2) were also protected from developing
severe EAU as indicated by reduction of inflammatory cells in
their eyes (Fig. 2D; right panel) and significant reduction in their
EAU scores (Fig. 2E). However, reduction of EAU severity was
more dramatic in mice treated under Protocol 1. These results
indicate that while the drug did not prevent the initiation of
uveitis, it was effective at reducing the severity of ongoing disease.
ORLL-NIH001 inhibited the expansion of uveitogenic
Th17 cells
To characterize the mechanism by which ORLL-NIH001
inhibited EAU, we isolated draining LN cells from vehicle-treated
(control) or drug-treated mice on day-18 post-immunization
(Protocol 1) and re-stimulated the cells in vitro with IRBP for 4
days. Thymidine incorporation assay performed on the cells
revealed that ORLL-NIH001 significantly inhibited proliferation
of the IRBP-responsive CD4
+ T cells; the proliferative capacity of
drug-treated cellswas decreased bymore than three-folds compared
to cells from mice treated with vehicle alone (Fig. 3A). To further
examine effects of the drug before onset of disease, we isolated
PBMC from individual mice 4 days post-immunization and
quantified the relative levels of in vivo circulating CD4
+ T cells in
the vehicle- or drug-treated mice. FACS (Fluorescence-Activated
Cell Sorting) analysis revealed significantly lower numbers of CD4
+
T cells in their peripheral blood in the drug-treated mice even
before the onset of EAU (Fig. 3B), suggesting that ORLL-NIH001
induced reduction in the numbers of activated IRBP-primed
uveitogenic T cells that exit the LN and enter the blood. Analysis
of the relative abundance of Th1 and Th17 cells among the
peripheral blood CD4
+ T cell population further revealed that the
drug-treated mice contained substantially reduced levels of Th17
cells compared to control mice treated with vehicle alone (Fig. 3C).
Interestingly, the inhibitory effects of ORLL-NIH001 were most
dramatic on Th17-DP (compare 2.78% to 0.55%) (Fig.3C). On the
other hand, the drug had marginal effects on the levels of Th1 cells
in the PBMC (Fig. 3C) or draining LN (Fig. 3D), regardless of
whether the mice were treated under Protocol 1 or 2. CFSE analysis
of the IRBP-stimulated LN cells also revealed marked reduction in
the level of resting or proliferating IL-17-expressing T cells in the
drug treated mice, further underscoring effects of ORLL-NIH001
on Th17 cells (Fig. 3E).
Figure 2. ORLL-NIH001 conferred protection from development of severe EAU. (A) Schematic depiction of immunization protocols used
for EAU induction in B10.A mice. Mice treated under Protocol 1 received injections of ORLL-NIH001, starting 1 day before immunization (day 21) and
on every other day thereafter until day-17 post-immunization. Protocol 2: mice began receiving the drug on day-5 post-immunization. Mouse eyes
were harvested, fixed, embedded in paraffin and stained with H&E. (B, D) Histological analysis showing: inflammatory cells in the vitreous (black
arrows), retinal folds (white arrows). OpN, optic nerve; V, vitreous; GCL, ganglion cell layer; INL, inner nuclear layer; ONL, outer nuclear layer. (C, E) EAU
scores were calculated for vehicle-treated (control) or ORLL-NIH001-treated mice based on and histology. Similar results were obtained in mice
treated under Protocol 1 (B, C) or Protocol 2 (D, E) and data presented are representative of at least 3 independent experiments.
doi:10.1371/journal.pone.0029742.g002
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dependent
To further characterize effects of ORLL-NIH001 on CD4
+ and
CD8
+ T lymphocytes, we isolated naı ¨ve CD4
+ or CD8
+ T cells
from B10A mice, labeled the cells with CFSE and then cultured
them for 4 days under Th17 or Tc17 polarization condition in
medium containing vehicle alone or different doses of ORLL-
NIH001. We show here that the drug inhibited the proliferation of
IL-17-expressing CD4
+ and CD8
+ T cells in a dose-dependent
manner (Fig. 4A). The dose-dependent inhibitory effects of
ORLL-NIH001 were further confirmed by the Thymidine
incorporation assay (Fig. 4B).
STAT3-inhibitors inhibit expression proteins that mediate
lymphocyte trafficking into the retina
Integrins play important roles in the extravasation of lympho-
cytes into CNS tissues [20] and resistance of CD4-STAT3KO
mice to EAU or EAE derives in part from defects in the expression
of integrins that mediate trafficking of uveitogenic or encephalito-
genic T-cells into the CNS during EAU or EAE [12]. We therefore
examined whether reduction in inflammatory cells observed in the
retina of mice treated with ORLL-NIH001 (Fig. 2), derived from
the inhibition of integrins, adhesion molecules and/or chemokine
receptors expression. Draining LN cells from mice with EAU were
re-stimulated with IRBP and analyzed by FACS for the expression
of molecules implicated in chemotaxis and homing of lymphocytes
into CNS tissues. Compared to control mice, CD4
+ T cells from
drug-treated mice expressed much reduced levels of CD49d
(integrin a4) and CD29 (integrin b1) and the activation VLA-4
(a4b1 was markedly inhibited by ORLL-NIH001 (Fig. 5A). IRBP-
specific LN T cells from drug-treated mice also expressed much
reduced levels of the Th1- and Th17-specific chemokine receptors,
CXCR3 and CCR6 (Fig. 5A). These results were reproduced and
validated by similar studies using two well-characterized and
commercially available selective inhibitors of STAT3: (i) a cell-
permeable phosphopeptide that inhibits STAT3 by binding to
STAT3-SH2 domain (STAT3 peptide) (Calbiochem, La Jolla, CA);
Figure 3. ORLL-NIH001 inhibited expansion of mouse uveitogenic Th17 cells. (A) Draining LN cells from vehicle-treated (control) or drug-
treated mice (Protocol 1) were re-stimulated in vitro with IRBP for 3 days and effects of ORLL-NIH001 was assessed by Thymidine incorporation assay.
Freshly isolated PBMC (B, C) was isolated from individual mice 4 days post-immunization. The levels of CD3
+CD4
+ T cells were quantified using FACS
(B) and the number of cytokine-expressing T cells was assessed by intracellular cytokine assay (C). (D, E) Freshly isolated lymph node cells from vehicle
or drug-treated mice were re-stimulated ex vivo with IRBP for 3 days and then analyzed by the intracellular cytokine assay. CFSE was added to some
cultures (E). Plots were gated on CD3
+ T cells and numbers in quadrants indicate percent of CD4
+ T cells expressing IL-17 and/or IFN-c. Data
presented are representative of at least 3 independent experiments.
doi:10.1371/journal.pone.0029742.g003
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activation and STAT3-dependent transcription (S31-201) (Calbio-
chem, La Jolla, CA). We further show that the expression of a4b7
integrin that promotes lymphocyte migration and CD44 that
mediates leukocytes adhesion were also inhibited by ORLL-
NIH001 in a dose dependent manner (Fig. 5B). These results
suggest that ORLL-NIH001 mitigated EAU, in part, by inhibiting
recruitment of uveitogenic T cells into the retina.
ORLL-NIH001 inhibited the expansion of human Th17
cells
Our data showing that ORLL-NIH001 inhibited the recruit-
ment of inflammatory cells into mouse retina and mitigated EAU
raised the tantalizing question of whether it has similar inhibitory
effects on human lymphocytes. To investigate whether ORLL-
NIH001 can inhibit the expansion of human T cells we isolated T
cells from peripheral blood of normal human volunteers,
stimulated the cells with anti-CD3/anti-CD28 Abs for 4 days in
medium containing the vehicle or varying doses of ORLL-
NIH001. We show here that ORLL-NIH001 inhibited the
proliferation of Th17 and Th1 cells (Fig. 6A). It is however of
note that, the drug primarily targeted highly proliferating cells
(Fig. 6A). Similar to the inhibitory effects of ORLL-NIH001 on
mouse IRBP-specific T cells that mediated EAU, the suppression
of human Th17 expansion by ORLL-NIH001 was dose-
dependent (1 to 5 mM). To determine whether ORLL-NIH001
selectively targeted STAT3 pathway in human lymphocytes,
CD4
+ T cells from human PBMC were activated with anti-CD3/
CD28 abs for 4 days, cultured in serum-free medium for 2 hours
and then stimulated with IL-6 in medium containing vehicle alone
or ORLL-NIH001 (10 mM). Consistent with its specificity for
STAT3, ORLL-NIH001 inhibited STAT3 phosphorylation of
human and mouse cells but had marginal effects on STAT1 or
STAT5 activation (Fig. 6B–E). We further show by intracellular
staining assay that the inhibitory effects of ORLL-NIH001 on
STAT3 activation is dose-dependent (Fig. 6F, G). Similar to our
Western blotting data, we did not observe substantial suppression
of STAT1 or STAT5 activation (Fig. 6F–H).
Discussion
Human uveitis is a diverse group of chronic intraocular
inflammatory diseases that can lead to blindness and they include
Figure 4. ORLL-NIH001 inhibits expansion of Th17 cells in a dose dependent manner. (A, B) Naı ¨ve CD4
+ and CD8
+ T cells were labeled with
CFSE, stimulated for 4 days with anti-CD3/anti-CD28 under Th17 polarization condition in medium containing vehicle alone or different doses of
ORLL-NIH001 (A). Numbers in the quadrants indicate percent of proliferating or non-proliferating CD4
+ or CD8+ T cells expressing IL-17. (B)
Proliferation of cells in cultures without CFSE was quantified by the Thymidine incorporation assay. Data presented are representative of at least 3
independent experiments.
doi:10.1371/journal.pone.0029742.g004
Small Molecule Inhibitor of STAT3 Inhibits Uveitis
PLoS ONE | www.plosone.org 6 January 2012 | Volume 7 | Issue 1 | e29742sympathetic ophthalmia, birdshot retinochoroidopathy, Behc ¸et’s
disease, Vogt-Koyanagi-Harada syndrome, pars planitis, and
ocular sarcoid [21,22,23]. Blinding uveitis is characterized by
repeated cycles of remission and recurrent intraocular inflamma-
tion and although steroids and other anti-inflammatory drugs are
effective therapy, renal toxicity or other adverse effects preclude
prolonged usage [22,24]. Involvement of Th17 and Th17-DP cells
in mouse [12,25] and human uveitis [4] suggest that they may be
potential targets for treating uveitis. Given the essential role of
STAT3 in Th17 cell differentiation and effector functions, proof-
of-principle experiments showing that genetic ablation of STAT3
in T cells prevented development of EAU and EAE in mice
[12,13], provided impetus to develop drugs that target STAT3
pathways for treating uveitis and other autoimmune diseases
mediated by Th17 cells.
In this study, we have shown that ORLL-NIH001, a small
molecule that targets STAT3 pathways in T cells was effective in
mitigating uveitis in mice. The drug-treated mice contained
substantially reduced levels of Th17 cells compared to control
mice treated with vehicle alone (Fig. 2). Interestingly, the
inhibitory effects of ORLL-NIH001 on T cell expansion were
most dramatic onTh17-DP and it is of note that a strong
correlation has previously been noted between the expansion of
the Th17-DP subtype in the blood, LN and retina and the
development of uveitis in the mouse [4,12]. These results are
consistent with previous report showing that the resistance of
CD4-STATKO mice to EAU or EAE development derived from
failure to generate Th17 cells, marked reduction in the expression
of activated a4/b1 integrins and inability of pathogenic Th17/
Th1 cells to traffic into the retina or brain [12]. a4b1 and a4b7
integrins have been implicated in chronic demyelinating diseases
[26,27,28,29]. Recent studies have shown that a4b1 mediates the
recruitment of immature dendritic cells across the blood-brain
barrier [30] and is required for entry of encephalitogenic T cells
into the CNS during EAE [31,32]. On the other hand, how a4b7
contributes to EAE pathogenesis is not well understood, as ectopic
expression of MAdCAM-1 at the blood-brain barrier failed to
increase a4b7-mediated immune cell trafficking into the CNS
during EAE [33]. Nonetheless, inhibiting the a4 subunit of the
integrin heterodimers, a4b1 and a4b7, with the mab natalizumab
has been found to be effective in the treatment of multiple sclerosis
(MS) [34]. Although the involvement of a4b1 and a4b7 has not
been established in EAU, the extensive distribution of adhesion
molecules on the endothelium of the vessels in the retina and iris in
patients with uveitis suggest their potential role in the development
of the disease [35].
In this study, we observed that decrease in inflammatory cells in
the eyes of mice treated with ORLL-NIH001 correlated with the
down-regulation of activated a4b1 a4b7 CCR6 and CXCR3 and
the inhibitory effects of ORLL-NIH001 derived in part from
inhibiting the tyrosine phosphorylation of STAT3 in response to
pro-inflammatory proteins. We have also shown that a cell-
permeable phosphopeptide molecule, as well as, an amidosalicylic
acid compound that bind to STAT3-SH2 domain inhibited
STAT3 activation and the expression of CXCR3 and CCR6,
suggesting that ORLL-NIH001 may in part ameliorate EAU by
inhibiting STAT3-dependent transcription. Together, these results
indicate that ORLL-NIH001 mitigates uveitis by 2 distinct
mechanisms: It inhibits Th17 differentiation/expansion and
prevents entry of inflammatory cells into the neuroretina. It is
notable that EAU was markedly inhibited in mice that were
treated with ORLL-NIH001 1 day before disease induction, as
well as, mice that received the drug after establishment of the
disease process, suggesting potential value of ORLL-NIH001 in
treating pre-existing uveitis. Although delivery of ORLL-NIH001
by intravenous injection is effective for treating EAU, we are
currently exploring alternative routes for delivery of the drug, such
as subcutaneous injection, oral administration or direct injection of
ORLL-NIH001 into the eye.
The pathway towards Th17 differentiation in mouse and
humans are also regulated by two retinoic acid receptor-related
orphan nuclear receptors, RORct and RORa [36,37,38]. Loss of
expression of these Th17 lineage transcription factors prevents
differentiation of Th17 cells and development of Th17-mediated
autoimmune diseases in mice [5]. In a recent report digoxin and its
derivatives were found to inhibit mouse Th17 differentiation and
ameliorate EAE [7]. In another report a synthetic ligand, SR1001,
specific to RORct and RORa exhibited similar inhibitory effects
Figure 5. ORLL-NIH001 inhibited proteins that mediate lymphocyte trafficking into retina. (A, B) LN cells from mice with EAU were re-
stimulated with IRBP in medium containing ORLL-NIH001 or commercially available STAT3 inhibitors. Expression or activation of integrins and
chemokine receptors were analyzed by FACS. Plots were gated on CD4
+ T cells and numbers in quadrants indicate percent of CD4
+ T cells expressing
CD11a, CD29, CD44, CD49d, CXCR3, CCR6, a4b7a4b1 or Ly6c. Data presented are representative of 3 independent experiments.
doi:10.1371/journal.pone.0029742.g005
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PLoS ONE | www.plosone.org 7 January 2012 | Volume 7 | Issue 1 | e29742on Th17 development and EAE [6]. These reports, together with
results presented in this study usher a new therapeutic approach
for treatment of autoimmune diseases and the challenge is to
develop non-toxic small molecule compounds that can effectively
target Th17 transcription factors. Although all three molecules,
ORLL-NIH001, SR1001 and the non-toxic digoxin derivates,
ameliorate EAU or EAE by inhibiting Th17 differentiation and
antagonizing IL-17 expression/maintenance of Th17 phenotype,
ORLL-NIH001 has the additional benefit of also inhibiting the
trafficking of inflammatory cells into the CNS tissues. ORLL-
NIH001 was not cytotoxic to mouse or human cells at
concentrations that inhibited EAU, making it suitable candidate
drug for treatment of human autoinflammatory disease. However,
as is the case with RORct and RORa, STAT3 is expressed in
other cell types and long-term treatment with any of these
inhibitors of Th17 development may have unwanted side effects.
Nonetheless, it is important to note that treatment for patients with
relapsed or refractory posterior uveitis or panuveitis remains
challenging and prolonged use standard anti-uveitic therapy is
associated with significant risk of developing cataract and
Figure 6. ORLL-NIH001 inhibited the expansion of human Th17 cells. (A) CD4
+ T cells isolated from PBMC of healthy human subjects were
labeled with CFSE and then stimulated with anti-CD3/CD28 for 4 days in medium containing vehicle alone or different doses of ORLL-NIH001.
Numbers in the quadrants indicate percent of proliferating or non-proliferating T cells expressing IL-17 or IFN-c. (B) Human PBMC were activated with
anti-CD3/CD28 abs for 4 days, stimulated with IL-6 in serum-free medium containing vehicle or ORLL-NIH001. The cells were then analyzed for the
expression of STAT3, pSTAT1 or b-actin by Western blotting. Activated human (C) or mouse (D–H) CD4 T cells were stimulated with IL-2 or IL-6 and
expression of pSTAT1, pSTAT3 and pSTAT5 was detected by Western blotting (C, D, E) or flow cytometry (F, G, H). (E) Western blots (B, C, D) were
analyzed using NIH Image Quant program and each band was normalized to corresponding b-actin band and expressed in arbitrary relative protein
expression units. Results are representative of 3 independent experiments.
doi:10.1371/journal.pone.0029742.g006
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PLoS ONE | www.plosone.org 8 January 2012 | Volume 7 | Issue 1 | e29742glaucoma [22,24]. Thus, a small molecule such as ORLL-NIH001
that selectively target a critical transcription factor that plays
critical roles in recruitment of inflammatory cells into the immune-
privileged neuroretina offer an attractive alternative for treating
these potentially blinding diseases.
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